Company intelligence / Profile preview

Innovalve Bio Medical

Ownership: Private
Development stage: Preclinical

Overview

Innovalve developed a minimally invasive transcatheter mitral valve replacement system ("Innostay") that has received FDA approval to begin human feasibility trials in the US. Early clinical experience is described as promising, with the device designed to form a tight seal within the mitral valve by manipulating and anchoring native tissue for improved outcomes in patients unsuitable for open surgery.

Therapeutic areas: Cardiovascular
Modalities: Device
Industry: Implantable Medical Devices

Partnerships

Edwards Lifesciences (initial investor since 2017, now acquirer)Sheba Medical Center spin-out

Beyond the preview

Go deeper on Innovalve Bio Medical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Innovalve Bio Medical.

Explore the full profile